Biologics IP – A Strategic Review (TechVision)

Biologics IP – A Strategic Review (TechVision)

Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics

RELEASE DATE
10-Aug-2016
REGION
Global
Research Code: D6AE-01-00-00-00
SKU: HC02669-GL-TR_18911
AvailableYesPDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC02669-GL-TR_18911

$4,950.00

$3,712.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.

Table of Contents

1.0 Executive Summary

2.1 Research Objective

2.2 Biologics versus Small Molecule

2.3 Big Pharma Shifting Focus from Small Molecule to Biologics, Why?

2.4 Big Pharma Gained Biologics Expertise through Mergers and Acquisitions (M&A)—Important Deals

3.1 Research Scope and Concepts

3.2 Analysis Approach

3.3 Keywords and IPC Codes Used for Clustering by Biologics Type

3.4 Therapeutic Areas Covered in the Study

4.1 Competitive Benchmarking of the Top 13 Major Pharma Companies Based on Their Biologics Patent Portfolios, 1996–2015

5.1.1 Mapping of Roche’s Patent Portfolio by Biologics Type

5.1.2 Mapping of Roche’s Patent Portfolio by Therapeutic Area

5.2.1 Mapping of GSK’s Patent Portfolio by Biologics Type

5.2.2 Mapping of GSK’s Patent Portfolio by Therapeutic Area

5.3.1 Mapping of Merck’s Patent Portfolio by Biologics Type

5.3.2 Mapping of Merck’s Patent Portfolio by Therapeutic Area

5.4.1 Mapping of Sanofi’s Patent Portfolio by Biologics Type

5.4.2 Mapping of Sanofi’s Patent Portfolio by Therapeutic Area

5.5.1 Mapping of Novartis’s Patent Portfolio by Biologics Type

5.5.2 Mapping of Novartis’s Patent Portfolio by Therapeutic Area

5.6.1 Mapping of Bristol-Meyers Squibb’s Patent Portfolio by Biologics Type

5.6.2 Mapping of Bristol-Meyers Squibb’s Patent Portfolio by Therapeutic Area

5.7.1 Mapping of Amgen’s Patent Portfolio by Biologics Type

5.7.2 Mapping of Amgen’s Patent Portfolio by Therapeutic Area

5.8.1 Mapping of Novo Nordisk’s Patent Portfolio by Biologics Type

5.8.2 Mapping of Novo Nordisk’s Patent Portfolio by Therapeutic Area

5.9.1 Mapping of Pfizer’s Patent Portfolio by Biologics Type

5.9.2 Mapping of Pfizer’s Patent Portfolio by Therapeutic Area

5.10.1 Mapping of Eli Lilly’s Patent Portfolio by Biologics Type

5.10.2 Mapping of Eli Lilly’s Patent Portfolio by Therapeutic Area

5.11.1 Mapping of AstraZeneca’s Patent Portfolio by Biologics Type

5.11.2 Mapping of AstraZeneca’s Patent Portfolio by Therapeutic Area

5.12.1 Mapping of Bayer HealthCare’s Patent Portfolio by Biologics Type

5.12.2 Mapping of Bayer HealthCare’s Patent Portfolio by Therapeutic Area

5.13.1 Mapping of AbbVie’s Patent Portfolio by Biologics Type

5.13.2 Mapping of AbbVie’s Patent Portfolio by Therapeutic Area

6.1 Key Findings

Legal Disclaimer

7.1 Acronyms

8.1 The Frost & Sullivan Story

8.2 Value Proposition: Future of Your Company & Career

8.3 Global Perspective

8.4 Industry Convergence

8.5 360º Research Perspective

8.6 Implementation Excellence

8.7 Our Blue Ocean Strategy

Related Research
This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.
More Information
No Index No
Podcast No
Author Manmohan Singh
Industries Healthcare
WIP Number D6AE-01-00-00-00
Is Prebook No
Ti Codes D910,D913,D91A,D935